Market closed
Tango Therapeutics/$TNGX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
Ticker
$TNGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
140
Website
TNGX Metrics
BasicAdvanced
$334M
-
-$1.14
0.88
-
Price and volume
Market cap
$334M
Beta
0.88
52-week high
$12.99
52-week low
$2.59
Average daily volume
1.1M
Financial strength
Current ratio
8.004
Quick ratio
7.803
Long term debt to equity
15.169
Total debt to equity
16.418
Management effectiveness
Return on assets (TTM)
-22.37%
Return on equity (TTM)
-48.80%
Valuation
Price to revenue (TTM)
7.732
Price to book
1.46
Price to tangible book (TTM)
1.46
Price to free cash flow (TTM)
-2.723
Growth
Revenue change (TTM)
15.67%
Earnings per share change (TTM)
3.34%
3-year revenue growth (CAGR)
2.35%
3-year earnings per share growth (CAGR)
8.35%
What the Analysts think about TNGX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
TNGX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TNGX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TNGX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $334M as of January 31, 2025.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of January 31, 2025.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.